Plain-English translation of NCT06742307 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new approach to treating wet age-related macular degeneration using faricimab, a medication injected directly into the eye. After you receive a few initial loading doses to get your eye disease stable, you would then receive the medication as a regular maintenance injection every 12 to 16 weeks. The goal is to determine whether this quarterly schedule can maintain your vision while reducing the burden of frequent clinic visits.
Many patients with wet macular degeneration currently need eye injections every 4 to 8 weeks, which is a heavy burden on eye clinics and can be costly for patients. This trial is exploring whether spacing out injections to every three to four months could work just as well, making treatment more sustainable and accessible.
You likely qualify if…
You likely don't qualify if…
You would first receive two to four loading doses of the medication as initial injections into your eye, spaced a few weeks apart. Once your eye disease becomes stable and inactive, you would then switch to a maintenance schedule of injections every 12 to 16 weeks. Each injection is a quick outpatient procedure performed at the hospital clinic, and you would be monitored regularly to ensure your vision remains stable on this schedule.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Hong Kong